Skip to content

mNGS Was Applied to the Study of Pathogen Identification, Precision Medication and Efficacy Evaluation of Infected Patients

mNGS Was Applied to the Study of Pathogen Identification, Precision Medication and Efficacy Evaluation of Infected Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04310657
Enrollment
200
Registered
2020-03-17
Start date
2020-10-01
Completion date
2023-09-30
Last updated
2020-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mNGS

Brief summary

1\) prospectively collected the patients with the proposed infection, confirmed the infection or excluded the infection through mNGS detection combined with traditional pathogen detection methods and clinical characteristics, compared the detection performance of mNGS and traditional methods, and explored the significance of mNGS microbial map characteristics for the diagnosis/exclusion of infection; 2) real-time dynamic monitoring of the pathogen and microecology of infected patients during the targeted drug use, and evaluation of the efficacy in combination with other indicators; 3) to explore the significance of the number of pathogen sequences before the clinical withdrawal of drugs to the clinical practice.

Interventions

DIAGNOSTIC_TESTmNGS

Metagenomics second generation sequencing technology

Sponsors

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* 18 to 75 years old * expected length of stay in ICU was \> 24 h * suspected infected patients (PSI or CPIS, qSOFA or SIRS)

Exclusion criteria

* Pregnant and lactating women * Who has not signed the informed consent * the researchers considered that others were not suitable for the study

Design outcomes

Primary

MeasureTime frameDescription
28-day mortality28 days28-day mortality

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026